Replies to post #86012 on SMART MONEY GROUP

[TheFinalCD]

Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial

https://finance.yahoo.com/news/madrigal-mgl-3196-achieves-primary-115500496.html

why couldnt we have 1-2k of this premarket

$54-$101



l;ol